IBD Flashcards

1
Q

What is the most common age for the diagnosis of IBD?

A

20-30’s but can occur at any age

may be a second peak in 70’s - 80’s

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the key features of Crohn’s disease?

A

Idiopathic, chronic inflammatory condition
Involves anywhere from mouth - anus
Relapses and remissions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is the characteristic presentation of Crohn’s disease?

A

Abdominal pain and diarrhoea
often indolent onset
other symptoms include rectal bleeding, fever, weight loss, malnutrition, bone loss, and vitamin deficiencies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is the pathophysiologiy of Crohn’s?

A

Defective regulation of Th1 cells causes chronic inflammation
Th1 cells release cytokines - IL12 and TNF alpha, interferon gamma which stimulate an inflammatory response
Inflammatory cells release inflammatory mediators
- arachidonic acid metabolites, proteases, platelet activating factor, and free radicals, which result in direct injury to the intestine

Increased production of TNF-α by macrophages in patients with Crohn disease results in increased concentrations of TNF-α in the stool, blood, and mucosa

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are the macroscopic findings of Crohn’s?

A

Initial findings of hyperaemia and oedema of mucosa
Superficial ulcers which can be serpiginous giving a cobblestone appearance
Skip lesions
Thickening of bowel and narrowing of lumen due to transmural inflammation - strictures can form
Advance disease: deep ulceration can lead to fistulas, micro perforation, abscess formation, adhesions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are the histological findings of Crohn’s?

A
Inflammatory infiltrate around crypts
Ulceration of superficial mucosa
Non-caseating granulomas
- inflammatory cells invade deeper mucosal layers forming non-caveating granulomas*
Transmural inflammation
Crypt abscesses
- due to neutrophil invasion of crypts
Villous blunting 
  • Although granuloma formation is pathognomonic of Crohn disease, its absence does not exclude the diagnosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Name the genetic abnormalities associated with Crohn’s?

A

More than 70 genes have been found to be involved

NOD2/CARD15

  • a polymorphic gene involved in the innate immune system.
  • 3 single nucleotide polymorphisms (SNPs) play a role in 27% of patients with Crohns, primarily ill disease

IL23R gene

  • encodes 1 subunit of IL-23 receptor protein
  • 2 SNPs identified

TG16L1 gene, which encodes the autophagy-related 16-like protein involved in the autophagosome pathway that processes intracellular bacteria

IRGM gene SNP
mounting evidence that the autophagosome pathway is very important in the pathogenesis of the disease.

XBP1 gene, which is involved in the unfolded protein response pathway of the endoplasmatic reticulum.[52][53] Other well documented genes which increase the risk of developing Crohn disease are ATG16L1,[54] IL23R,[55] IRGM,[56] and SLC11A1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are the non-genetic risk factors for Chron’s?

A

Infectious agents such as Mycobacterium paratuberculosis, Pseudomonas species, and Listeria species have all been implicated in the pathogenesis of Crohn disease, suggesting that the inflammation seen with the disease is the result of a dysfunctional, but appropriate, response to an infectious source

Smoking - doubles risk

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is the typical rates of involvement of parts of the large bowel in UC

A

Proctitis/proctosigmoiditis 30-50%
Left sided colon 20-30%
Pan-colitis 20%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is the pathogenesis of UC?

A

Largely unknown
Possible abnormal induction of T2 cells to secrete various cytokines causing superficial mucosal inflammation
Possible abnormal immune response to gut flora

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are some genetic associations with UC (syndromes + specific gene mutations)

A
IL-23R mutation
STAT 3
Jak2
Turners syndrome
Hermansky-pudlack
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is the risk of a patient with UC having a first degree relative affected?

A

10-25%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Clinical manifestations of UC

A
Freq, small volume diarrhoea
Blood/mucus/pus in BM
Tenesmus, urgency
Colicky abdo pain
Fever, fatigue, weight loss
Symptoms of anaemia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is the severity classification for UC?

A

Mild - less then 4 BM per day, small Blood, normal ESR, no fever, normal haemodynamics
Moderate - 4-6 BM per day with moderate blood, low grade fever, mild anaemia, low grade fever
Severe - greater then 6 BM per day, large blood, febrile, tacy, ESR greater then 30
Fulminant - greater then 10 BM per day with large blood and haemodynamic instability

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Extra-intestinal manifestations of UC

A
Enteropathic arthropathy
Ankylosing spondylitis
Osteopenia/osteoporosis/osteonecrosis
Uveitis/episcleritis/iritis/conjunctivitis
Erythema nodosum
Pyoderma gangrenosm
PSC
Fatty liver
Increased risk of arterial and venous clots
Autoimmune haemolytic anaemia
  • all except PSC, uveitis, ank spon correlate and flare with disease flares
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Biopsy findings in UC

A

Macro - granular, erythematous mucosa, friable, oedematous mucosa, no skip lesions, back-wash ileitis seen in severe cases

Micro - limited to mucosa, crypt abscesses, atrophy, lymphoid infiltrates

17
Q

Complications of UC

A

Acute - massive haemorrhage, toxic mega colon, perforation

Chronic - stricture (malignant until proven otherwise), dysphasia and malignancy

18
Q

Typical disease course of UC

A

Relapsing and remitting disease

Proctitis - generally benign course, responds to topical therapy
Those with younger age of diagnosis, fever, weight loss, flare within 2 years of diagnosis have a high risk of relapse
20-30% require colectomy at some stage

19
Q

Recommendations for colorectal ca screening in UC

A

No increased risk for those with proctitis or proctosigmoiditis - no screening required over normal population

Others:
Every 1-2 years after presence of pancolitis for 8-10 years
Every 1-2 years after presence of left sided colitis 12-15 years prior

20
Q

Action of 5-amigos alicyclics acid medications

A

Induce PPAR-gamma gene expression leading to the suppression of cytokine activation

21
Q

What are the indications for antibiotics in UC

A

Used in pouchitis (post surg complication) and toxic megacolon
Treatment of c.diff infection - higher rates of metronidazole resistance, used oral vanc first line

22
Q

What is TPMT and why is it important?

A

Enzyme that metabolises 6-MP to a toxic metabolite (6-MMP)
1 in 300 individuals lack significant TPMT activity leading to increased production of 6-TGN (active metabolite) leading to myelotoxicity and marrow suppression

23
Q

How does allopurinol effect thiopurine metabolism

A

Inhibits xanthene oxidase which increases the amount of 6-MP that is metabolised to active metabolite (6-TGN) and decreases shunting to other inactive metabolites

Can be used in shunters (low levels of 6-TGN but high levels of 6-MMP) in combination with reducing dose

24
Q

What is the action of thiopurine medications

A

6-TGN inhibits purine and ribonucleotide synthesis and T + B cell proliferation

25
Q

How long do thiopurines take to work?

A

1-6 months

26
Q

What is the action of Cyclosporin?

A

Calcineurin inhibitor - blocks production of IL2

27
Q

What is infliximab?

A

Anti-TNF alpha therapy

Chimeric (human/mouse) IgG1 antibody against TNF alpha

28
Q

What are some problems with infliximab?

A

Development of antibodies to Infliximab - reduced response

Increased risk of lymphoma especially hepatosplenic T-cell lymphoma (fatal, common in young men)

29
Q

Screening prior to starting infliximab?

A

Hep B, HIV, varicella
Tb - quantiferon or mantoux
Any evidence of old Tb requires treatment for latent T

30
Q

Indications for surgery in UC

A
Failed medical therapy
Fumlinant disease
Toxic mega colon not responding to 72 hours of medical therapy
Peroration
Massive haemorrhage 
Colon cancer
31
Q

Preferred surgical treatment of UC?

A

Illegal pouch anal anastamosis

  • preserves continence, stool freq 6-8 per day
  • affects fertility
  • complicated by pouchitis
32
Q

Treatment for mild to mod Proctitis/proctosigmoiditis

A

Remission - topical ASA
Maintaince - ongoing ASA

Steroid foams can be used second line but are less effective

33
Q

Treatment for mild/mod colitis

A

Combination oral and topical 5-ASA
Oral steroid if fails to respond to above

Maintain with ongoing ASA and reduce steroids after effect seen (usually 2 weeks)

34
Q

What is steroid dependant UC

A

Inability to taper steroids to less than 10mg per day within 3 months of starting steroids or relapse within 3 months of stopping steroids

Exclude other diagnosis - CMV, CDiff etc.
Consider bridge to thiopurine with Cyclosporin or infliximab

35
Q

What is steroid refractory UC

A

No reponse to high dose oral steroids over 30 days or IV 7-10’days

36
Q

Treatment of severe colitis

A

If well enough trial high dose oral steroids and oral and topical ASA
If too unwell or not responding - IV steroids
If not responding in 7-10’days consider infliximab or Cyclosporin bridging

37
Q

Treatment of fulminant colitis

A

IV steroids
Review at 3 days
If no response Cyclosporin or infliximab

38
Q

What is better Cyclosporin vs infliximab in UC

A

RCTs have shown same outcomes = equivalent

Ideal with infliximab is use with thiopurine as this reduces risk of antibody development

39
Q

What are some other management issues in UC

A

Cancer screening - colon, cervical, non melanoma skin cancer with thiopurine use
VTE prevention during admission
vit d supplementation
Immunisation